Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Pictet Biotech Class I - Income (GBP)

Sell:59,820.00p Buy:59,820.00p Change: 520.00p (0.86%)
Prices as at 16 October 2019
Sell:59,820.00p
Buy:59,820.00p
Change: 520.00p (0.86%)
You can buy or sell holdings in this fund through an ISA, Lifetime ISA, SIPP or Fund & Share Account
Prices as at 16 October 2019
Sell:59,820.00p
Buy:59,820.00p
Change: 520.00p (0.86%)
Prices as at 16 October 2019
You can buy or sell holdings in this fund through an ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Our view on this Fund

This fund does not feature on our Wealth 50 list of what we believe are the best funds in each sector. If a fund is not within our Wealth 50 this is not necessarily a recommendation to sell. However, if you are thinking of adding to your investments we believe Wealth 50 funds are superior alternatives. View funds on the Wealth 50 »

Our view on the sector

Our view on the sector for this fund is not available.

Performance Analysis

Performance analysis for this fund is not available.

Investment Philosophy

Investment philosophy for this fund is not available.

Process and Portfolio Construction

Process and portfolio construction for this fund are not available.

question mark Manager Track Record Based on HL Quantitative Research

This information is currently unavailable.

Fund Track Record

16/10/14 to 16/10/15 16/10/15 to 16/10/16 16/10/16 to 16/10/17 16/10/17 to 16/10/18 16/10/18 to 16/10/19
Annual return 26.20% 3.44% 20.59% -5.39% -1.47%

Please remember past performance is not a guide to future returns. Where no data is shown, figures are not available. This information is provided to help you choose your own investments, remember they can fall as well as rise in value so you may not get back the original amount invested.

Information about the fund

Fund manager biography

manager photo
Manager Name: Lydia Haueter
Manager start date: 1 February 2018
Manager located in: TBC

Lydia Haueter joined Pictet Asset Management in 2016 and is an Investment Manager in the Thematic Equities team. Lydia began her career in 2011 at Bellevue Asset Management as an analyst covering biotech stocks; there she became an investment manager (small-mid cap biotech). Lydia graduated with a Master of Science in Systems Biology from ETH Zürich and she is Chartered Financial Analyst (CFA) charterholder.

Manager Name: Moritz Dullinger
Manager start date: 1 September 2018
Manager located in: TBC

Moritz Dullinger joined Pictet Asset Management in 2018 as a Senior Investment Manager for Pictet-Health within the Thematic Equities team. Before joining Pictet, Moritz was responsible for the RobecoSAM ?Healthy Living? equity fund. Prior to this, he was a project manager responsible for strategic healthcare investments at a portfolio company of the Carlyle Group. He started his career as a sell side equity research analyst at Kepler Cheuvreux covering European healthcare stocks. Moritz holds a Bachelor's in Economics from the University of Hagen. He is also a Chartered Financial Analyst (CFA) and Chartered Alternative Investment Analyst (CAIA) charterholder.

manager photo
Manager Name: Tazio Storni
Manager start date: 26 May 2016
Manager located in: Zurich

Tazio Storni joined Pictet Asset Management in October 2014 as a Senior Investment Manager in the Sector & Theme Funds team. He began his investment career in 2005 with UBS Global Asset Management, as a financial analyst covering Biotech, Medtech and Chemical companies. In 2010 he took over the responsibility for the UBS (Lux) Equity Health Care fund. Prior to joining Pictet Asset Management Tazio worked for Bellevue Asset Management as lead portfolio manager on the BB Biotech (Lux) Fund. He holds a Masters in Biology and a PhD in Immunology from the Eidgenössische Technishe Horchschule in Zurich (ETH). Tazio is a Chartered Financial Analyst (CFA) charterholder.

manager photo
Manager Name: Gregoire Biollaz
Manager start date: 1 April 2016
Manager located in: TBC

Grégoire Biollaz joined Pictet Asset Management in 2016 and is a Senior Investment Manager in the Thematic Equities team. Prior to joining Pictet, Grégoire was a Senior Equity Analyst at the family office Aeris Capital, responsible for the global Healthcare sector. Before this he worked at Credit Suisse as a buy-side Senior Equity Analyst covering the global Healthcare and Chemicals sectors. Prior to entering the financial industry, Grégoire worked as a Research Scientist at Immunex, at that time one the world's fastest growing biotech companies, now part of Amgen. Grégoire holds a PhD in Biochemistry and a Master of Science in Biology, both from Eidgenössische Technische Horchschule in Zurich (ETH).

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Benchmark data provided subject to this disclaimer.
You can buy or sell holdings in this fund through an ISA, Lifetime ISA, SIPP or Fund & Share Account